We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVVD icon
326
Invivyd
IVVD
$238M
$371K 0.09%
424,933
+307,396
+262% +$385K
JANX icon
327
Janux Therapeutics
JANX
$995M
$371K 0.09%
24,130
+6,309
+35% +$91.4K
ABUS icon
328
Arbutus Biopharma
ABUS
$1B
$369K 0.09%
76,807
+18,912
+33% +$83K
PHVS icon
329
Pharvaris
PHVS
$2.65B
$368K 0.09%
10,651
-635
-6% -$19.2K
VRDN icon
330
Viridian Therapeutics
VRDN
$2.47B
$368K 0.09%
20,012
+11,573
+137% +$186K
BLTE
331
Belite Bio
BLTE
$6.81B
$365K 0.09%
2,369
+440
+23% +$67.4K
NAMS icon
332
NewAmsterdam Pharma
NAMS
$2.56B
$365K 0.09%
10,763
+3,444
+47% +$113K
ANL
333
Adlai Nortye Group ADS
ANL
$1B
$365K 0.08%
+31,705
New +$386K
EFT
334
Eaton Vance Floating-Rate Income Trust
EFT
$279M
$364K 0.08%
33,745
-12,149
-26% -$131K
AURA icon
335
Aura Biosciences
AURA
$708M
$362K 0.08%
+51,045
New +$365K
ELVN icon
336
Enliven Therapeutics
ELVN
$3.62B
$360K 0.08%
7,093
-9,080
-56% -$385K
SYRE icon
337
Spyre Therapeutics
SYRE
$8.09B
$360K 0.08%
4,050
-4,060
-50% -$296K
EYPT icon
338
EyePoint Inc
EYPT
$298M
$359K 0.08%
25,111
+8,059
+47% +$108K
STOK icon
339
Stoke Therapeutics
STOK
$1.82B
$359K 0.08%
10,973
+2,555
+30% +$82K
ARVN icon
340
Arvinas
ARVN
$534M
$359K 0.08%
43,166
+21,490
+99% +$200K
ALLO icon
341
Allogene Therapeutics
ALLO
$601M
$358K 0.08%
172,209
-8,379
-5% -$18.4K
RAPP
342
Rapport Therapeutics
RAPP
$2.01B
$355K 0.08%
8,521
-486
-5% -$17.9K
BLW icon
343
BlackRock Limited Duration Income Trust
BLW
$473M
$354K 0.08%
28,365
-2,569
-8% -$32.2K
NGNE icon
344
Neurogene
NGNE
$680M
$354K 0.08%
11,244
-1,789
-14% -$49.3K
IMTX icon
345
Immatics
IMTX
$1.33B
$353K 0.08%
34,882
+7,723
+28% +$81.6K
CMPX icon
346
Compass Therapeutics
CMPX
$328M
$353K 0.08%
161,181
+108,335
+205% +$320K
IRON icon
347
Disc Medicine
IRON
$2.66B
$352K 0.08%
4,812
+1,845
+62% +$127K
LXEO icon
348
Lexeo Therapeutics
LXEO
$342M
$349K 0.08%
74,874
+46,964
+168% +$254K
BKT icon
349
BlackRock Income Trust
BKT
$320M
$347K 0.08%
32,326
-5,903
-15% -$62.4K
GAIN icon
350
Gladstone Investment Corp
GAIN
$637M
$344K 0.08%
22,223
-18,810
-46% -$295K
12 13
14
15 16

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.